drugset / Trial / NCT01218880
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-07
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M2ES | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 15 mg/m2 | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 30 mg/m2 | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 45 mg/m2 | Intravenous |